reviewed april 2026|next review october 2026|88 physicians psi has verified|1849 published studies
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea with obesity. It is the first dual-receptor peptide agonist to reach market.
Evidence landscape: 1849 published studies
1,849 published items: 47 human studies and 103 animal studies. A clinical-trial-driven evidence base supporting three FDA-approved indications across the SURPASS and SURMOUNT Phase III programs.
- 47 Human
- 103 Animal
- 50 Reviews
- 1649 Other research
FDA-approved prescription medicine in the United States under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management; obstructive sleep apnea with obesity).
The SURPASS program (type 2 diabetes) and SURMOUNT program (weight management) comprise multiple large Phase III trials. SURMOUNT-1 documented 22.5% mean body weight reduction at the highest dose, the largest weight loss in any approved anti-obesity medication trial to date.
Unlike semaglutide, tirzepatide does not yet have completed cardiovascular outcomes data. The SURPASS cardiovascular outcomes trial (SURPASS-CVOT) is ongoing but has not reported. SUMMIT demonstrated heart failure outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, but that is a different endpoint.
PSI Assessment
The weight loss results from the SURMOUNT Phase III program were the largest ever reported for an FDA-approved medication: up to 22.5% of body weight over 72 weeks. Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management, is the first dual-receptor agonist to reach market, activating both GLP-1 and GIP pathways at once. It is now approved for three indications including obstructive sleep apnea. The open questions are long-term durability, cardiovascular outcomes (trial ongoing), and how it performs head-to-head against the incoming triple agonists.
The largest weight loss in any approved anti-obesity medication trial. Cardiovascular outcomes data is still pending.
The mechanism adds GIP receptor agonism on top of GLP-1. GIP, glucose-dependent insulinotropic polypeptide, improves insulin sensitivity and modifies how adipose tissue stores and releases fat. The dual activation is the mechanistic reason weight loss results have been larger than GLP-1-only medications. In a head-to-head trial (SURPASS-2), all three tirzepatide doses produced greater weight and blood sugar reductions than semaglutide at its diabetes dose. The FDA indication has expanded unusually fast, now covering type 2 diabetes, chronic weight management, and obstructive sleep apnea.
What the evidence supports
FDA-approved for type 2 diabetes, weight management, and obstructive sleep apnea. Largest weight loss of any approved medication (22.5% in SURMOUNT-1). Superior to semaglutide at its diabetes dose in head-to-head trial (SURPASS-2).
What is not yet established
Cardiovascular outcomes (SURPASS-CVOT ongoing, not reported). Long-term weight maintenance after stopping treatment. Head-to-head comparison against semaglutide at its obesity dose (2.4 mg). How it compares to triple agonists entering the pipeline.
Research Evidence
The findings below cover what the Phase III programs established and the key gap relative to semaglutide.
Evidence by condition
Evidence dimensions across tirzepatide's approved and investigated indications. Weight management and type 2 diabetes have the deepest evidence. Cardiovascular outcomes remain the key gap relative to semaglutide.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Weight Management | ||||
| Type 2 Diabetes | ||||
| Obstructive Sleep Apnea | ||||
| Heart Failure (HFpEF with obesity) | ||||
| Non-alcoholic Steatohepatitis (MASH) |
SURMOUNT-1 demonstrated up to 22.5% mean body weight reduction at the 15 mg dose over 72 weeks. This is the largest weight loss in any approved anti-obesity medication trial to date.
Before tirzepatide, this magnitude of weight loss typically required bariatric surgery. It is the effect size that led to Zepbound approval and shifted the ceiling of what is achievable with medication.
In the SURPASS-2 head-to-head trial, all three tirzepatide doses produced greater HbA1c and body weight reductions than semaglutide 1 mg in adults with type 2 diabetes.
This trial compared tirzepatide to the type 2 diabetes dose of semaglutide (1 mg), not the 2.4 mg obesity dose. The magnitude and consistency of the difference was enough to shift prescribing patterns in diabetes care.
Phase II data supports MASH resolution and fibrosis improvement, and Phase III programs are ongoing. SUMMIT demonstrated improved heart failure outcomes in adults with HFpEF and obesity.
The evidence base is expanding beyond diabetes and weight into liver disease and heart failure. These are separate Phase III programs, not post-hoc analyses, and they support the mechanism's breadth.
47 Human|103 Animal|50 Reviews
View all 1849 indexed studiesHow Tirzepatide Works
Tirzepatide is a 39-amino-acid synthetic peptide, which means it is a short chain of building blocks that normally make up proteins. It is designed to mimic two different natural fullness hormones at the same time, GIP and GLP-1, instead of just one.
Your body produces two hormones after eating: GLP-1 and GIP. Both tell your brain you have had enough food, but they work through different pathways. Most weight loss medications only mimic GLP-1. Tirzepatide mimics both. Think of it as sending two separate fullness signals at the same time instead of one. The result is a stronger reduction in appetite and potentially better metabolic effects than targeting GLP-1 alone.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Tirzepatide is a 39-amino-acid synthetic peptide based on the GIP sequence with engineered GLP-1 receptor agonist activity. A fatty diacid chain attached at Lys20 promotes albumin binding and extends the half-life to approximately five days. It activates the GIP receptor with equivalent potency to native GIP and the GLP-1 receptor with approximately 5-fold lower potency than native GLP-1. The dual receptor activation produces complementary effects on insulin secretion, glucagon suppression, gastric motility, and central appetite regulation through distinct but overlapping hypothalamic pathways. GIP signaling may also contribute to fat oxidation and adipose tissue remodeling that GLP-1 alone does not.
What is Tirzepatide being studied for?
Researchers are studying Tirzepatide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Tirzepatide overall. This means a compound can have human studies for one condition but only animal data for another.
Weight Management
·FDA ApprovedSURMOUNT-1 demonstrated mean body weight reduction of up to 22.5% at the 15 mg dose over 72 weeks. FDA-approved for chronic weight management as Zepbound.
Limitations: Most participants were female and white. Long-term data beyond 72 weeks is still accumulating. Weight regain after discontinuation is a known consideration shared with the GLP-1 class.
Type 2 Diabetes
·FDA ApprovedThe SURPASS program demonstrated HbA1c reductions superior to placebo, insulin comparators, and semaglutide 1 mg. FDA-approved for type 2 diabetes as Mounjaro.
Limitations: Head-to-head comparison against semaglutide was at the T2D dose (1 mg), not the obesity dose (2.4 mg). Gastrointestinal side effects can limit tolerability.
Obstructive Sleep Apnea
·FDA ApprovedSURMOUNT-OSA Phase III trials demonstrated reduced sleep apnea severity and body weight in adults with obesity and moderate-to-severe OSA. FDA-approved for this indication.
Limitations: Evidence is specific to obesity-related OSA. Effect in non-obese OSA populations is not established.
Heart Failure (HFpEF with obesity)
·FDA ApprovedThe SUMMIT trial demonstrated improved functional status and heart failure outcomes in adults with heart failure with preserved ejection fraction and obesity.
Limitations: Specific to HFpEF with obesity. Does not generalize to HFrEF or non-obese heart failure populations. Cardiovascular outcomes trial SURPASS-CVOT remains ongoing.
Non-alcoholic Steatohepatitis (MASH)
·Human TrialsThe Phase II SYNERGY-NASH (tirzepatide in metabolic dysfunction-associated steatohepatitis) trial showed significant MASH resolution and fibrosis improvement versus placebo. Phase III programs are ongoing.
Limitations: Phase II, not confirmatory. No FDA approval for MASH yet. Biopsy-defined cohorts.
Safety and Regulatory Status
FDA Status: FDA-approved in the United States as Mounjaro (T2D) and Zepbound (chronic weight management; obstructive sleep apnea with obesity).
Prescription status: Prescription-only in the United States. A doctor can write a prescription for it with an appropriate clinical indication. Versions prepared outside the FDA-regulated supply chain have been associated with dosing errors and quality concerns.
International status: Approved in major international jurisdictions including the European Medicines Agency (EMA), the United Kingdom Medicines and Healthcare products Regulatory Agency, and Health Canada for type 2 diabetes and weight management.
Common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are dose-dependent and generally transient but can limit tolerability. The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies; this has not been observed in humans. A 2026 retrospective study (Liu et al., J Clin Endocrinol Metab) reported modest bone mineral density loss in semaglutide and tirzepatide users tied to weight loss. Bone density loss was similar to matched controls in patients with diabetes; in non-diabetic users, the GLP-1 RA group lost modestly more at the total hip (-1.0% vs -0.6% over 17 months). The pattern is consistent with bariatric surgery and severe caloric restriction, suggesting the effect is weight-loss-mediated rather than a direct drug action. Adults at baseline fracture risk, including post-menopausal women, older adults, and anyone with prior osteopenia or osteoporosis, should discuss bone density monitoring with their physician. Long-term cardiovascular outcomes data is still being collected.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Tirzepatide discussion.
Comparison and Related Research
Tirzepatide is most often compared with other metabolic peptides in the GLP-1 and multi-receptor agonist classes. The comparisons below outline how each differs in mechanism, evidence base, and regulatory status.
Head-to-head comparisons
Full research comparisons covering Tirzepatide and another peptide side by side.
Tirzepatide vs Semaglutide
Evidence-based comparison of semaglutide and tirzepatide for weight management. Side-by-side analysis of mechanisms, clinical outcomes, evidence strength, and safety profiles.
View full comparisonTirzepatide vs Ozempic
Evidence-based comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide), the FDA-approved type 2 diabetes brands. SURPASS-2 head-to-head, SELECT cardiovascular outcomes, brand-indication map, and PSI assessment.
View full comparisonTirzepatide vs Wegovy
Evidence-based comparison of Wegovy (semaglutide) and Zepbound (tirzepatide), the FDA-approved chronic weight management brands. SURMOUNT-5 head-to-head, SELECT cardiovascular outcomes, brand-indication map, and PSI assessment.
View full comparisonTirzepatide vs Retatrutide
Evidence-based comparison of tirzepatide (FDA-approved dual GIP/GLP-1 agonist) and retatrutide (investigational triple-receptor agonist in Phase III). SURMOUNT-1, TRIUMPH-4, head-to-head magnitude analysis, dysesthesia safety signal, and PSI assessment.
View full comparisonTirzepatide vs Semaglutide
Three-way comparison of semaglutide, tirzepatide, and retatrutide for metabolic health. Evidence levels, receptor mechanisms, clinical data, and research maturity analyzed.
View full comparisonTirzepatide vs related compound
Neutral, factual explanation that Mounjaro and Zepbound are both tirzepatide, with differences centered on approved indication, labeling, and use context.
View full comparisonTirzepatide vs Survodutide
Both are dual agonists. Tirzepatide pairs GLP-1 with GIP. Survodutide pairs GLP-1 with glucagon. Different second targets, different clinical profiles.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Landmark SURMOUNT-1 trial demonstrating up to 22.5% mean body weight reduction with tirzepatide 15 mg over 72 weeks in adults with obesity without diabetes.Jastreboff AM et al., 2022 in N Engl J Med. View on PubMed
- 2.Head-to-head SURPASS-2 trial showing tirzepatide superior to semaglutide 1 mg on HbA1c and body weight reductions across all tested tirzepatide doses in type 2 diabetes.Frías JP et al., 2021 in N Engl J Med. View on PubMed
- 3.SURPASS-1 monotherapy trial demonstrating significant HbA1c and body weight reductions with tirzepatide versus placebo in adults with type 2 diabetes inadequately controlled by diet and exercise.Rosenstock J et al., 2021 in Lancet. View on PubMed
- 4.SURPASS-3 trial showing tirzepatide superior to insulin degludec on glycemic control and weight in type 2 diabetes inadequately controlled on metformin.Ludvik B et al., 2021 in Lancet. View on PubMed
- 5.SURPASS-4 trial demonstrating superior glycemic control and weight reduction with tirzepatide versus insulin glargine in type 2 diabetes patients with high cardiovascular risk.Del Prato S et al., 2021 in Lancet. View on PubMed
- 6.SURMOUNT-2 trial demonstrating weight management efficacy of tirzepatide in adults with obesity and type 2 diabetes over 72 weeks.Garvey WT et al., 2023 in N Engl J Med. View on PubMed
- 7.SURMOUNT-OSA Phase III trial demonstrating reduced sleep apnea severity and body weight with tirzepatide, supporting expanded FDA indication for obstructive sleep apnea in obesity.Malhotra A et al., 2024 in N Engl J Med. View on PubMed
- 8.SUMMIT trial evaluating tirzepatide in patients with heart failure with preserved ejection fraction and obesity, demonstrating improvement in functional status and heart failure outcomes.Packer M et al., 2024 in N Engl J Med. View on PubMed
- 9.SYNERGY-NASH Phase II trial demonstrating significant MASH resolution and fibrosis improvement with tirzepatide versus placebo.Sanyal AJ et al., 2024 in N Engl J Med. View on PubMed
- 10.SURPASS-5 trial showing tirzepatide added to insulin glargine produced substantial HbA1c reduction and weight loss versus placebo in inadequately controlled type 2 diabetes.Dahl D et al., 2022 in JAMA. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.